A Pilot, Phase II Study With a Prospective, Randomized, Cross-Over, Placebo-Controlled, Double-Blind Design to Assess the Short-Term Effects of Tolvaptan Plus Placebo vs Tolvaptan Plus Octreotide LAR Combination Therapy in ADPKD Patients With Normal Kidney Function or Hyperfiltration
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs Octreotide (Primary) ; Tolvaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Therapeutic Use
- Acronyms TOOL
- 01 Jul 2019 Status changed from not yet recruiting to recruiting.
- 30 Aug 2018 Planned End Date changed from 1 Jul 2020 to 1 Sep 2020.
- 30 Aug 2018 Planned primary completion date changed from 1 Jul 2020 to 1 Sep 2020.